Probabilistic Approach to Generating MPOs and Its Application as a Scoring Function for CNS Drugs

ACS Medicinal Chemistry Letters

Volumn 7, Issue 1, 2016, Pages 89-93

  Gunaydin, Hakan ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

CNS; MPO; Multiparameter optimization

Indexed keywords

CENTRAL NERVOUS SYSTEM AGENTS;

ACCURACY; ALGORITHM; AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DEGRADATION; DRUG DESIGN; LIPOPHILICITY; MOLECULAR WEIGHT; MULTIPARAMETER OPTIMIZATION; PRIORITY JOURNAL; PROBABILITY; PROCESS OPTIMIZATION; SCORING SYSTEM;

EID: 84955468444     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/acsmedchemlett.5b00390     Document Type: Article

References (13)

1. Gatlik-Landwojtowicz, E.; Aanismaa, P.; Seelig, A. Quantification and characterization of P-glycoprotein-substrate interactions Biochemistry 2006, 45, 3020-3032 10.1021/bi051380+
2. Gunaydin, H.; Weiss, M. M.; Sun, Y. De novo prediction of p-glycoprotein-mediated efflux liability for druglike compounds ACS Med. Chem. Lett. 2013, 4, 108-112 10.1021/ml300314h
3. Wager, T. T.; Liras, J. L.; Mente, S.; Trapa, P. Strategies to minimize CNS toxicity: in vitro high-throughput assays and computational modeling Expert Opin. Drug Metab. Toxicol. 2012, 8, 531-542 10.1517/17425255.2012.677028
4. Di, L.; Kerns, E. H.; Carter, G. T. Drug-like property concepts in pharmaceutical design Curr. Pharm. Des. 2009, 15, 2184-2194 10.2174/138161209788682479
5. Hill, A. P.; Young, R. J. Getting physical in drug discovery: a contemporary perspective on solubility and hydrophobicity Drug Discovery Today 2010, 15, 648-655 10.1016/j.drudis.2010.05.016
6. Rankovic, Z. CNS drug design: balancing physicochemical properties for optimal brain exposure J. Med. Chem. 2015, 58, 2584-2608 10.1021/jm501535r
7. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Delivery Rev. 2001, 46, 3-26 10.1016/S0169-409X(00)00129-0
8. Wager, T. T.; Hou, X.; Verhoest, P. R.; Villalobos, A. Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties ACS Chem. Neurosci. 2010, 1, 435-449 10.1021/cn100008c
9. Estrada, A. A.; Sweeney, Z. K. Chemical Biology of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors J. Med. Chem. 2015, 58, 6733-6746 10.1021/acs.jmedchem.5b00261
10. Egan, W. J.; Merz, K. M., Jr.; Baldwin, J. J. Prediction of drug absorption using multivariate statistics J. Med. Chem. 2000, 43, 3867-3877 10.1021/jm000292e
11. Bickerton, G. R.; Paolini, G. V.; Besnard, J.; Muresan, S.; Hopkins, A. L. Quantifying the chemical beauty of drugs Nat. Chem. 2012, 4, 90-98 10.1038/nchem.1243
12. Labuzek, K.; Suchy, D.; Gabryel, B.; Bielecka, A.; Liber, S. et al. Quantification of metformin by the HPLC method in brain regions, cerebrospinal fluid and plasma of rats treated with lipopolysaccharide Pharmacol. Rep. 2010, 62, 956-965 10.1016/S1734-1140(10)70357-1
13. Nosten, F.; ter Kuile, F. O.; Luxemburger, C.; Woodrow, C.; Kyle, D. E. et al. Cardiac effects of antimalarial treatment with halofantrine Lancet 1993, 341, 1054-1056 10.1016/0140-6736(93)92412-M